pharmacology of a drug approved by fda in 2010
TRANSCRIPT
![Page 1: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/1.jpg)
PBRS 2015-Regulatory Sciences6 May 2015
Pharmacokinetic propertiesPharmacokinetic properties Pharmacodynamic propertiesPharmacodynamic properties
Pharmacology of a Drug Approved by FDA in 2010Pharmacology of a Drug Approved by FDA in 2010
SILENOR (DOXEPIN)SILENOR (DOXEPIN)
Mirza Danish Hussain Barlas Assistant Manager Business Development and Regulatory Affairs
(Pharm-D , R.Ph, MBA-Mkt, MBA-SC, CRCP)
![Page 2: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/2.jpg)
Disclaimer
The information withinthis presentation is based on the
References, the Presenter's Interest andRegulatory Experience.
![Page 3: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/3.jpg)
The FDA Drug Approval Process
The FDA-CDER ensures that drugs marketed are safe and effective. It conducts limited research in the areas of drug quality, safety, and effectiveness.
1. Investigational New Drug (IND) Application 2. New Drug Application (NDA) 3. Abbreviated New Drug Application (ANDA): Generics 4. Therapeutic Biologic Applications (BLA) 5. Drug Applications for Over-the-Counter (OTC) Drugs
![Page 4: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/4.jpg)
The Problem
Insomnia and Sleep Maintenance Difficulty. Types of Insomnia 1.Transient (short term) insomnia. 2.Chronic (long term) insomnia.
![Page 5: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/5.jpg)
The Symptoms Not being able to fall asleep. Waking frequently during the night. Waking too early. Being unable to return to sleep.
![Page 6: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/6.jpg)
The Psychology
![Page 7: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/7.jpg)
The Complications
![Page 8: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/8.jpg)
The Solution
Silenor (Doxepin) Tablets 3mg and 6mg
A low-dose oral tablet formulation of the H1 receptor Antagonist Doxepin.
![Page 9: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/9.jpg)
The Generic
Doxepin
![Page 10: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/10.jpg)
The Pharmacology
Silenor binds with high affinity to histamine (H1) receptors. This mechanism of action is different from that of any other prescription medication currently approved for the treatment of insomnia.
![Page 11: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/11.jpg)
Pharmacodynamics
.
1. The mechanism of action of doxepin is not definitely known. 2. It is not a central nervous system stimulant nor a monoamine oxidase
inhibitor. The current hypothesis is that the clinical effects are due, at least in part, to influences on the adrenergic activity at the synapses so that deactivation of nor-adrenaline by reuptake into the nerve terminals is prevented.
3. Silenor binds with high affinity to histamine (H1) receptors which makes it a H1 receptor Antagonist.
![Page 12: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/12.jpg)
Pharmacokinetics
.
AbsorptionDoxepin is well absorbed from the gastro-intestinal tract.
Approximately 55%-87% of orally administered doxepin undergoes first pass metabolism in the liver.
This forming the primary active metabolite desmethyldoxepin.
Peak plasma concentrations for doxepin ranging from 8.8-45.8 ng/ml
Peak levels were reached between 2 and 4 hours after administration.
Peak levels for the primary metabolite desmethyldoxepin ranged from 4.8-14.5 ng/ml (mean 9.7 ng/ml)
Peak levels were achieved between 2 and 10 hours after administration.
![Page 13: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/13.jpg)
Pharmacokinetics
.
DistributionThe mean apparent volume of distribution for doxepin is approximately 20 l/kg.
The protein binding for doxepin is approximately 76%.
The plasma elimination half-life of doxepin ranged from 8 to 24 hours.
The half-life of desmethyldoxepin ranged from 33-80 hours.
Mean plasma clearance for doxepin is approximately 0.84 1/kg/hr.
![Page 14: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/14.jpg)
Pharmacokinetics
.
MetabolismPaths of metabolism of doxepin include: 1.Demethylation2.N-oxidation 3.Hydroxylation4.Glucuronide formation
![Page 15: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/15.jpg)
Pharmacokinetics
.
Excretion Doxepin is excreted primarily in the urine, mainly as its metabolites, either free or in conjugate form.
![Page 16: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/16.jpg)
The Side Effects
The Side Effects that are known to occur are 1. Somnolence2. Sedation3. Nausea4. Upper respiratory tract infection
![Page 17: Pharmacology of a Drug Approved by FDA in 2010](https://reader035.vdocuments.net/reader035/viewer/2022062523/58f181c61a28ab574f8b45d5/html5/thumbnails/17.jpg)
The References
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1090/silenor-doxepin
http://www.drugs.com/newdrugs/somaxon-announces-fda-approval-silenor-doxepin-insomnia-2070.html